Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

NBIX

+ Watchlist+ Portfolio

Neurocrine Biosciences, Inc.

Regulated industryPhysical productsTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$165.92
52-Week Range
$122.14 – $186.12
Market Cap
$16.48B
P/E (TTM)
24.16
EPS (TTM)
6.74
Dividend Yield
0.00%
Advanced Metrics
Price/Book
4.25
PEG Ratio
0.33
Return on Equity
20.41%
Return on Assets
12.45%
Gross Margin
64.67%
Operating Margin
26.62%
Profit Margin
18.98%
Current Ratio
2.04
Debt/Equity
0.12
Total Debt
$451.80M
Free Cash Flow
$1.02B
Revenue Growth
41.20%
Earnings Growth
-3.90%
Enterprise Value
$16.20B

Market Snapshot

About

Neurocrine Biosciences, Inc. discovers and develops treatments for neurological, neuroendocrine, and neuropsychiatric disorders. The company markets INGREZZA for tardive dyskinesia and develops a pipeline targeting conditions like schizophrenia, endometriosis, and congenital adrenal hyperplasia. Neurocrine focuses on diseases with significant unmet medical needs where neurological pathways play a central role.